News >

Telaglenastat Added to Everolimus Doubles PFS in Heavily Pretreated RCC

Jason M. Broderick @jasoncology
Published: Tuesday, Jun 18, 2019

Susan Molineaux, PhD

Susan Molineaux, PhD

Combining telaglenastat (CB-839) with everolimus (Afinitor) doubled the median progression-free survival (PFS) versus everolimus alone in heavily pretreated patients with advanced renal cell carcinoma (RCC), according to Calithera Biosciences, the company developing the glutaminase inhibitor.

Telaglenastat is also being explored in combination with cabozantinib (Cabometyx) in the phase II CANTATA trial. The double-blind trial is randomizing patients with advanced clear cell RCC to cabozantinib plus either placebo or telaglenastat. Patients must have received 1 or 2 prior lines of systemic therapy. The target enrollment is 400 patients and PFS is the primary endpoint. Data from the trial are anticipated from Calithera by the end of 2020.
Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma. Calithera Biosciences, Inc. Published online June 17, 2019. Accessed June 18, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication